Blood‐based biomarkers in Alzheimer disease: Current state of the science and a novel collaborative paradigm for advancing from discovery to clinic

TLDR

Research on blood‑based biomarkers for Alzheimer’s disease has surged in the past decade, driven by their cost‑efficiency, non‑invasiveness, and patient acceptability, yet reproducibility issues and unclear translation pathways remain major obstacles. The authors aim to review recent literature on blood‑based biomarkers for AD and propose a collaborative model to advance the field beyond discovery toward clinical application. They conducted a literature review and outlined a public‑private partnership model that combines academic and industry resources to streamline biomarker development. They identified key resources and presented a public‑private partnership framework designed to replace the conventional handoff model, offering a clear pathway for biomarker science in AD and other neurodegenerative diseases.

Abstract

Abstract The last decade has seen a substantial increase in research focused on the identification of blood‐based biomarkers that have utility in Alzheimer's disease (AD). Blood‐based biomarkers have significant advantages of being time‐ and cost‐efficient as well as reduced invasiveness and increased patient acceptance. Despite these advantages and increased research efforts, the field has been hampered by lack of reproducibility and an unclear path for moving basic discovery toward clinical utilization. Here we reviewed the recent literature on blood‐based biomarkers in AD to provide a current state of the art. In addition, a collaborative model is proposed that leverages academic and industry strengths to facilitate the field in moving past discovery only work and toward clinical use. Key resources are provided. This new public‐private partnership model is intended to circumvent the traditional handoff model and provide a clear and useful paradigm for the advancement of biomarker science in AD and other neurodegenerative diseases.